274
Participants
Start Date
August 31, 2008
Primary Completion Date
May 31, 2010
Study Completion Date
November 30, 2010
Aztreonam for Inhalation Solution (AZLI)
Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
Tobramycin Inhalation Solution (TIS)
Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
Dublin
Dublin
Dublin
Brussels
Brussels
Antwerp
Leuven
Maastricht
Ghent
New Hyde Park
Albany
Berlin
Caen
Lisieux
Hershey
Philadelphia
Philadelphia
Wilmington
Milan
Hamburg
Richmond
Madrid
Madrid
Madrid
Madrid
Málaga
Charleston
Orlando
Bordeaux
Pessac
Tampa
Montpellier
Rennes
Giessen
Verona
Magdeburg
Parma
Toledo
Bochum
Essen
Cincinnati
Essen
Dayton
Mainz
Lille
Glenview
Ancona
Chicago
Niles
Columbia
Oklahoma City
Paris
Houston
San Antonio
Aurora
Amiens
Napoli
Denver
München
Salt Lake City
Phoenix
Tuscon
Las Vegas
Palermo
Orange
Créteil
Catania
Anchorage
Berlin
Boston
Innsbruck
Salzburg
Copenhagen
Nice
Leipzig
Dublin
Galway
Rome
Rome
The Hague
Lisbon
Porto
Zurich
Zurich
Sheffield
Belfast
Cambridge
Cardiff
Leeds
Liverpool
London
Southampton
Lead Sponsor
Collaborators (2)
Chiltern International Inc.
INDUSTRY
ClinPhone, Inc.
INDUSTRY
Covance
INDUSTRY
Gilead Sciences
INDUSTRY